Pay in 4 interest-free payments of $6.53 Learn more
:format(webp))
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Beyond BED, bulimia nervosa (BN) also shares core features of impulsive, dysregulated eating and recurrent binge episodes, and GLP-1related satiety and reward pathways are likely relevant in both conditions [21]
Not an efficacy trial
GLP-1 Receptor Agonist Market Size and Trends Forecast: 2026 - 2033 GLP-1 receptor agonist market is estimated to be valued at USD 31.71 Bn in 2026 and is expected to reach USD 72.33 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033
For type 2 diabetes, alternatives to Semaglutide include other GLP-1 receptor agonists with similar efficacy but potentially different side effect profiles, like liraglutide or dulaglutide
